Synapse - Works

Results (197)

A multi-center collaborative study of outcomes of TP53- mutated MDS/AML patients following allogeneic HCT

Meeting Abstract

Byrne, M.; Kurian, T.; Patel, D.; Tamari, R.; Hong, S.; Abdelhakim, H.; Klein, V.; Rojas, P.; Madhavan, R.; Kent, A; more...
Transplantation and Cellular Therapy (2022)

Fulltext@MSK | Save

Encouraging outcomes after unrelated cord blood grafts for post-transplant relapse in pediatric patients

Meeting Abstract

Troullioud Lucas, A. G.; Boelens, J. J.; Kernan, N. A.; Prockop, S. E.; Curran, K. J.; Archer, A.; Davis, E.; Bresters, D.; Kollen, W.; Versluys, B.; more...
Transplantation and Cellular Therapy (2022)

Fulltext@MSK | Save

CAR-associated hemophagocytic lymphohistiocytosis (HLH) with use of commercial tisagenlecleucel in the Pediatric Real World Car Consortium (PRWCC): Risk factors and outcomes

Meeting Abstract

McNerney, K. O.; Lim, S. S.; Dreyzin, A.; Vatsayan, A.; Baggott, C.; Prabhu, S.; Pacenta, H. L.; Phillips, C. L.; Rossoff, J.; Stefanski, H. E.; more...
Transplantation and Cellular Therapy (2022)

Fulltext@MSK | Save

Double unit cord blood transplantation compares favorably to T-cell depleted matched adult donor transplantation for the treatment of acute leukemia due to a robust protection against relapse

Meeting Abstract

Politikos, I.; Flynn, J.; Devlin, S. M.; Fingrut, W.; Maloy, M. A.; Naputo, K.; Chinapen, S.; Rodriguez, N. T.; Quach, S.; Dominguez, Y.; more...
Transplantation and Cellular Therapy (2022)

Fulltext@MSK | Save

Cost-effectiveness of axicabtagene ciloleucel as secondline therapy for patients large B-cell lymphoma (LBCL) in the United States

Meeting Abstract

Perales, M. A.; Kuruvilla, J.; Snider, J. T.; Vadgama, S.; Blissett, R.; El-Moustaid, F.; Smith, N.; Patel, A.; Johnston, P. B.
Transplantation and Cellular Therapy (2022)

Fulltext@MSK | Save

Phase II trial of eprenetapopt (APR-246) in combination with azacitidine (AZA) as maintenance therapy for TP53 mutated acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) following allogeneic hematopoietic cell transplantation (HCT)

Meeting Abstract

Mishra, A.; Tamari, R.; DeZern, A. E.; Byrne, M.; Gooptu, M.; Bin, C.; Deeg, J.; Gallacher, P.; Wennborg, A.; Kaylor Hickman, D.; more...
Transplantation and Cellular Therapy (2022)

Fulltext@MSK | Save

IL-22 producing innate lymphocytes traffic to the intestinal stem cell compartment after conditioning-related radiation injury

Meeting Abstract

Fu, Y. Y.; Egorova, A.; Kuttiyara, J.; Hanash, A. M.
Transplantation and Cellular Therapy (2022)

Fulltext@MSK | Save

Defining the microbial ecosystem controlling antigen presentation by intestinal epithelium and acute GVHD in the gastrointestinal tract

Meeting Abstract

Koyama, M.; Srinivasan, S.; Hippe, D. S.; Proll, S. C.; Miltiadous, O.; Ensbey, K. S.; Hoffman, N. G.; Fiedler, T. L.; Kowalsky, J.; Schmitdt, K.; more...
Transplantation and Cellular Therapy (2022)

Fulltext@MSK | Save

Noninvasive genomic characterization of patients with nonsclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease identified a novel gene signature in responders to ruxolitinib cream

Meeting Abstract

Markova, A.; Whitaker, J. W.; Ai, R.; Pan, A.; Dusza, S.; Lacouture, M. E.; Chowdhury, A.; Perales, M. A.; Prockop, S. E.; Ponce, D. M.
Transplantation and Cellular Therapy (2022)

Fulltext@MSK | Save

Multicenter, open-label, phase 3 (P3) study of Tabelecleucel (Tab-cel) for solid organ (SOT) or allogeneic hematopoietic cell transplant (HCT) recipients with Epstein–Barr virus-driven post transplant lymphoproliferative disease (EBV(+) PTLD) after failure of rituximab (R) or rituximab and chemotherapy (R + C) (ALLELE)

Meeting Abstract

Prockop, S. E.; Mahadeo, K. M.; Beitinjaneh, A.; Choquet, S.; Stiff, P.; Reshef, R.; Satyanarayana, G.; Dahiya, S.; Mehta, A.; Dinavahi, R.
Transplantation and Cellular Therapy (2022)

Fulltext@MSK | Save